HEPATITIS C VIRUS (HCV) has been identified as a major cause of non-A,non-B hepatitis associated with blood transfusion."! The cloning of a portion of the genome of this virus" led to the development of a test for the detection of antibodies directed against a nonstructural component of the virus, 1 and it has been shown that this test will detect a substantial proportion of infectious blood donations." Anti-HCV testing is presently applied to whole blood and all transfusible components. However, until recently, the application of this test to plasma intended only for further manufacture into injectable products was discouraged by the United States Food and Drug Administration. This decision was based upon uncertainty about the effect such screening might have upon the concentration of HCV in plasma pools and about the contribution that antibodies to HCV might make to the safety of plasma derivatives, particularly immune globulin products."
In recent years, several reports of non-A,non-B hepatitis attributed to intravenous immune globulin have appeared. 8 -11 Although US-licensed immune globulin preparations have not been implicated in hepatitis transmission, the reasonsfor their apparentsafety are unclear. These preparations are made from large pools of plasma (undoubtedly containing HCV), and, in most cases, no deliberate virucidal step is employed in their manufacture. HCV may be removed and/or inactivated during the fractionation process. It is also possible that small amounts of HCV contaminating the immune globulin fraction might be neutralized by antibodies present in that fraction.
Recently, a number of investigators have applied the polymerase chain reaction (PCR) assay to the detection and quantitation of HCV RNA in biologic fluids l 2 -16 and in certain plasma derivatives.Pi" With a nested PCR, in which two sets of primers are used in sequence, a single copy of template cDNAcan be amplified to such an extent that the product is readily detected by ethidium bromide staining.P Time-consuming blotting and autoradiographic steps are thus unnecessary.Pi" The quantitation of HCV RNA can be achieved by limiting-dilution analysis.'?
The present study describes the use of nested PCR to examine the partitioning of HCV RNA during the fractionation of plasma to produce immune globulin. In addition, the effect of screening for anti-HCV upon the viral load of plasma pools was investigated.
Materials and Methods

Plasma collection and testing
The plasma used in these experiments was collected at plasmapheresis centers operated byAlpha 
Fractionation of anti-HCV-reactive plasma
We performed plasma fractionation by the process used by commercial fractionators, namely methods 6 and 9, respectively, of Cohn et al. 20 and Oncley et al.," modified as necessary for laboratory scale. Samples for PCR were taken at various stages as indicated ( Fig. 1) and were stored at -40°C until assayed. We carried out fractionation in a thermally insulated, 200-mL, stainless steel beakerand accomplished cooling and stirring by meansof a magnetic stirrerand a cold plate. The frozen, anti-HCV-reactive pool was thawed and brought to O°C, and then 100 mL was centrifuged (25 min, 16 ,000 x g) to collect the cryoprecipitate (Sample 1). We decanted the supernatant liquid (Sample2), adjusted it to pH 7.04, and then added95-percent ethanol to 8 percent(vobvol), while the mixture was stirred and cooled to -3°C. The suspension was held at this temperature for 30 minutes and then centrifuged (25 min, 16,000 x g, -3°C) to remove fraction I (Sample 3). We adjusted the supernatant I (Sample 4) to pH 6.76,21-percent ethanol at -5°C; it was stirred for 17 hours and then the mixture was centrifuged (25 min, 16,000 x g, -5°C) and 'LUD 10 'C the supernatant 11 + III decanted (Sample 5). The precipitate (fraction 11 + Ill) was suspended in 70 mL of ice water and stirred at 0 to 2°C for 1.5 hours (Sample 6); then the pH was adjusted to 6.68, and 95-percent ethanol was added to 20 percent while cooling to -5°C..After 1 hour, we centrifuged the mixture as above. The supernatant 11 +IIIw was decanted (Sample 7); the precipitate (fraction 11 +IIIw) was suspended in 94 mL of ice water, stirredfor 30 minutes at O°C, and then adjusted to pH 5.21 (Sample 8). We added ethanol to 17 percent while the mixture was cooledto -5°C; after it was stirred for 1 hour, we centrifuged the mixture as before. The fraction III precipitate (Sample 9) was harvested, supernatant III (Sample 10), at -5°C, was adjusted to pH 7.38, and ethanol was addedto increase the alcohol concentration to 25 percent.After l-hour stirring at -5°C, we centrifuged the mixture as before. The supernatant 11 (Sample 12)was decanted and the fraction 11 precipitate (Sample 11), 2.15 g, was stored at -400C. We dissolved a 1.08-g portion of fraction 11 in 4 mL of 0.01 M (0.01 mollL) sodium phosphate and 0.145M (0.145 mollL) NaCl, pH 7.4, and dialyzed it for 18 hours at 5°C against phosphate-bufferedsaline to remove residual ethanol. Afterdialysis, thissolution of IgG, at 34.1 mg of protein per mL, was frozen at -400C until analysis was performed (Sample 13).
Primers
All four primer sequences (5'.....3') were derived from the 5'-noncoding region of the HCV genome." We used Primer 1, ACfCCACCATAGATCACfCC (nts 07-26), and Primer2, GGTGCACGGTCfACGAGACCf (nts 304-324, reverse p0-larity), for the cDNA synthesis and the first PCR. Primer 3, ACfCCCCfGTGAGGAACfACf (nts 22-42), and Primer 4, AACACfACfCGGCfAGCAGT (nts 229·248, reverse polarity), were the inner primers nested within the outer pair and were used for the second PCR.
RNA extraction
We precipitated RNA from samples of plasma or plasma fraction by treatment with polyethylene glycolcompound (MW 15,000-20,000; SigmaChemical Co., St. Louis, MO)to a final concentration of 8 percent and held it at 4°C overnight. The pellet, obtained by centrifuging at 12,000 x g for 10 minutes at 4°C, was dissolved in 0. Perkin-Elmer). TheRTR wasperformed at 42°C for 15minutes and then for 3 minutes at 94°C to denature the avian myeloblastosis virus reverse transcriptase activity. We subsequently performed the PCRin the same tube for 25 cycles, each cycle consisting of 45 seconds at 94°C (denaturing), 45 seconds at 55°C (annealing), and 50 seconds at noc (extension). We subjected 10 ILL of the first PCR product to an additional 25 cycles of amplification with the second set of primers, using thesame ingredients andconditions as described above, except that we excluded the avian myeloblastosis virus reverse transcriptase andRNasin. Thesecond PCRproducts (10 ILL) were analyzed by electrophoresis in 1.2-percent agarose gel at 60 V for 1.5 hours, and amplified DNA species were visualized under ultraviolet light after being stained with ethidium bromide.
To estimate RCV RNA concentrations of samples, we subjected serial 1oo, s-fold (3.16-fold) dilutions of the RNA extracts to RTR andPCR. OnePCRunitwas arbitrarily defined as the minimum amount of HCV RNA from which an amplified product could be visualized. Inasmuch as the PCR procedure is capable of detecting a single template of cDNA,12.18 the number of PCR units in a sample is approximately equal to thenumber of copies of HCV RNA in the sample multiplied by the efficiency of the RTR,which has beenestimated to be about 5 percent." When all of the replicates at each dilution gave identical results (i.e., all positive or all negative), the greatest dilution giving a positive result wasconsidered to contain 1 PCR unit per replicate volume. When replicate assays were performed at a dilution suchthat not all of the replicates gavea positive reaction, the average amount of HCVRNA (in PCRunits) per replicate was taken as -In[fraction of negative reactions]. This method corrects for reactions thatcontain two or more template molecules, which cannot be distinguished from those containing onlyone molecule."
Results
Quantitation of HCVRNA in plasma samples
We determined the sensitivity of the PCR assay for HCV RNA by performing limiting-dilution analysis on a sample of infectious plasma (H strain) known to contain 1Q6 to 10' chimpanzee-infectious doses per mL.24 In our assay, this sample contained 1.4 x 10 6 PCR units of HCV RNA per mL (Table  1) . Thus, the PCR assay has a sensitivity comparable to the chimpanzee model. When plasma centers tested 3073 plasma donations from otherwise acceptable donors (i.e., who were nonreactive for antibody to human immunodeficiency virus type 1 and negative for hepatitis B surface antigen and who had alanine aminotransferase levels less than twice the upper limit of normal) for anti-HCV, 186 (6.1%) were repeatably reactive and 2887 were negative. A pool prepared from the anti-RCV-reactive donations contained 1.4 x 105 PCR units of HCVRNA per mL, whereas a pool prepared from the anti-HCV-negative donations contained 1.6 x l(P PCR units per mL (Table 1) . From these data, it can be calculated thata pool comprising all 3073 units would contain (186 x [1.4
x 105]
+ 2887 x [1.6 x 1()3])/3073 = 1.0 x 10" PCR units per mL. Thus, in this instance, anti-HCV screening decreased the viral loadof the plasma poolby a factor of 6.
Partitioning of HCVRNA during fractionation of plasma to immune globulin
We subjected a portion of the anti-RCV-reactive plasma pool to cold ethanol fractionation (see Fig. 1 ) and tested the variousfractions for RCV RNA by PCR. In the case of supernatants andsuspensions, the RNA wasextracted from 1 mL of solution. For analysis of solid fractions (i.e., cryoprecipiSample" (vol) tate, fraction I, fraction Il, and fraction m), one-fourth of the total precipitate obtained from the fractionation of 100 mL of plasma was suspended in 10 mL of phosphate-buffered saline, and the RNAwas extracted from 1 mL of this solution. As shown in Fig. 2 , when we tested undiluted RNA extracts of these samples, an amplified PCR product of the expected size (227 base pairs) was detected in all samples except supematant n+Illw, supematant m, and supematant n. The specificity of the RTR PCRwas demonstrated with positive (H strain) and negative control plasmas tested concurrently. It is of interest that HCV RNA was detected in fraction n,but not in supematant m(fromwhich fraction 11 is prepared), which suggests that both of these materials contain low levels of HCV RNA.
To quantify further the HCV RNA content of these fractions, we serially diluted the RNA extracts from the samples prior to RTR and PCR. The results (Table 2) were expressed as total PCR units contained in the fraction, and, because these results were derived from 3.16-fold serial dilutions, their accuracy is probably limited to a factor of 3 or 4. Of the HCV RNA in the starting plasma, about 50 percent was brought down with cryoprecipitate. The value obtained for the HCV RNA content of fraction I (8 x 1CJ6 PCR units) appears to be high by a factor of 2 or 3, as this value plus that for supematant I (3 x 1()6) should equal 6 x 1()6, the value for cryosupematant. Thus, precipitation of fraction I removed about 50 percent of the HCV RNA remaining in cryosupematant, so that supernatant I contained only 20 percent of the HCV RNA present in the starting plasma. Almost all of this was precipitated into fraction n+m; HCV RNA was detected in the supematant 11 + mwhen tested without dilution, but not when tested at 1 in lon· 5 
dilution. Suspension and reprecipitation of fraction
Il + malso resulted in the partitioning of all of the HCY RNA into fraction n+Illw; none was detected in the supematant n+ Illw, The same was true for the separation of fraction Ill, with virtually complete recovery of HCV RNA in this precipitate. Although HCV RNA was not detected in supematant m, low concentrations were found in the fraction 11 derived from this supematant and in the immune globulin produced from this fraction. Apparently, the level of HCV RNA in these materials was just at (or below) the limits of detectability (i.e., 1 
Discussion
It has been estimated that anti-HCV testing of plasma will detect about 80 percent of infectious donations." However, from this it cannot be assumed a priori that screening plasma for anti-HCV will result in an 80-percent decrease in the concentration of HCV in plasma pooled from thousands of donations. The effectiveness of anti-HCV screening in reducing theviral load of plasma pools depends not only upon the efficiency with which the test detects infectious units, but also uponthe relative viral titers in seropositive units and false-negative units, that is, those units containing HCV but devoid of anti-HCV. 7 If, on average, the latter contain HCV at substantially higher levels than the former, then anti-HCV screening will not be as effective in reducing the viral load of the pool as it is in reducing the number of infectious units pooled. The work reported here demonstrates that anti-HCV screening reduces the concentration of HCV in a large plasma pool by a factor of about 6 (83%), which is in good agreement with the reported sensitivity of the test. Thus, it appears that there is not a great disparity in the average viral titers of anti-HCVreactive units and false-negative units.
During Cohn-Oncley fractionation, most of the HCY RNApartitions into cryoprecipitate, fraction I, and fraction III, with trace amounts also found in supematant H+ III and fraction H. Plasma derivatives produced from cryoprecipitate (anti-hemophilic factor), cryosupematant (factor IX complex), and fraction I (fibrinogen, no longer licensed in the United States) are known to transmit HCV unless additional virus-inactivation steps are incorporated in their manufacture, so the observation that these fractions contain HCV RNA is not surprising. Products derived by further fractionation of supematant H+ III include antithrombin III, alpha-I proteinase inhibitor, plasma protein fraction, and albumin, all of which are subjected to heating for 10 hours at 60°C. The fact that these products do not transmit HCY may be due more L1T.001.3222 TRANSFUSION Vol. 32, No. to virus inactivation by the heating step than to physical removal of virus by the fractionation process. Because of the low level of HCV RNA found in supematant 11 + III (3 PCR units/mL), it was not possible to follow the distribution of viral RNA through the final fractionation steps leading to albumin.
The detection of HCY RNA in fraction 11, albeit at low levels, is noteworthy. Our work used a plasma pool "enriched" in HCY by a factor of 15 over an unscreened pool and by a factor of 90 over an anti-HCY-screened pool. Nevertheless, if the efficiency of virus removal is independent of the viral load in the starting plasma, one might expect to find substantial amounts of HCY RNA in immune globulin prepared from unscreened pools or even in that from anti-HCY-screened pools (60 and 10 PCR units of HCY RNNg IgG, respectively). Given that therapeutic doses of immune globulin range from 0.003 to 2 g per kg of body mass, and given the approximate equivalence of our PCR unit to a chimpanzee-infectious dose of HCV, it might seem that this product would have a high likelihood of transmitting HCV. There are several possible reasons why it apparently does not do so. 1) Intravenous immune globulin products undergo additional manufacturing steps that may, fortuitously, have virucidal properties; 2) the HCV RNA in immune globulin may not be infectious because of possible disruption of the viral envelope during the fractionation process; and 3) antibodies may be present in the immune globulin fraction that neutralize the infectivity of HCV. In spite of an excellent safety record, the detection of HCY RNA in immune globulin, coupled with sporadic reports of non-A,non-B hepatitis transmission by intravenous immune globulin, suggests thatvirus-inactivation and/or -removal stepsshould be considered for immune globulin products.
